Elizabeth Dawn Lightbody, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Paraffin Embedding | 1 | 2019 | 299 | 0.610 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 177 | 0.540 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 2505 | 0.490 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 871 | 0.470 |
Why?
|
| Multiple Myeloma | 7 | 2023 | 5180 | 0.420 |
Why?
|
| Gene Expression | 1 | 2019 | 7799 | 0.260 |
Why?
|
| Biosensing Techniques | 2 | 2019 | 668 | 0.210 |
Why?
|
| Peptide Elongation Factors | 1 | 2020 | 62 | 0.180 |
Why?
|
| Paraproteinemias | 1 | 2022 | 247 | 0.170 |
Why?
|
| Nurse's Role | 1 | 2021 | 209 | 0.170 |
Why?
|
| Bone Marrow | 3 | 2023 | 2944 | 0.150 |
Why?
|
| Formaldehyde | 1 | 2019 | 353 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2019 | 349 | 0.140 |
Why?
|
| Brain Ischemia | 2 | 2021 | 3265 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2023 | 933 | 0.140 |
Why?
|
| PPAR gamma | 1 | 2019 | 493 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2019 | 500 | 0.130 |
Why?
|
| Stroke | 3 | 2022 | 9981 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2022 | 2513 | 0.120 |
Why?
|
| Internationality | 1 | 2019 | 1003 | 0.120 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 996 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2019 | 2915 | 0.110 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2021 | 1052 | 0.110 |
Why?
|
| Phosphoproteins | 2 | 2018 | 2440 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2020 | 2967 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2018 | 2938 | 0.100 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 2158 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3176 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 4559 | 0.090 |
Why?
|
| Australia | 2 | 2022 | 1169 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2019 | 23404 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2019 | 3278 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 3646 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 2875 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 4837 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2019 | 3478 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 13096 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2019 | 12207 | 0.060 |
Why?
|
| Mice | 6 | 2023 | 81178 | 0.060 |
Why?
|
| Vietnam | 1 | 2022 | 408 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5319 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5221 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 20817 | 0.050 |
Why?
|
| Immunologic Tests | 1 | 2021 | 103 | 0.050 |
Why?
|
| Ascites | 1 | 2023 | 344 | 0.050 |
Why?
|
| Animals | 7 | 2023 | 168788 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3584 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 628 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 13668 | 0.040 |
Why?
|
| Humans | 17 | 2023 | 744220 | 0.040 |
Why?
|
| Plasma Volume | 1 | 2019 | 36 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2019 | 4201 | 0.040 |
Why?
|
| Interferons | 1 | 2023 | 706 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2021 | 527 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 552 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2022 | 1100 | 0.040 |
Why?
|
| Creatinine | 1 | 2023 | 1919 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 1143 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2022 | 1880 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 972 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 847 | 0.030 |
Why?
|
| Acyltransferases | 1 | 2018 | 294 | 0.030 |
Why?
|
| Disease Progression | 2 | 2022 | 13280 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 1261 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 2204 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2018 | 1724 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 664 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1582 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 3689 | 0.030 |
Why?
|
| Female | 8 | 2023 | 380197 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 6313 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3557 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 2161 | 0.030 |
Why?
|
| Base Sequence | 1 | 2023 | 12801 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2022 | 5974 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 25043 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2019 | 2751 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 6386 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2018 | 5180 | 0.020 |
Why?
|
| Risk | 1 | 2021 | 9685 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3598 | 0.020 |
Why?
|
| Genotype | 1 | 2023 | 12956 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 2848 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2022 | 4440 | 0.020 |
Why?
|
| Male | 5 | 2023 | 350027 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 3461 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9735 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12781 | 0.020 |
Why?
|
| Prevalence | 1 | 2022 | 15226 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2019 | 7730 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 14556 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 11368 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10480 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 8426 | 0.010 |
Why?
|
| Apoptosis | 1 | 2020 | 9728 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2023 | 77426 | 0.010 |
Why?
|
| Algorithms | 1 | 2023 | 13885 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 29050 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2022 | 40559 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 18027 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 53280 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 213367 | 0.000 |
Why?
|